Trial · NCT01518972

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

NCT01518972, Phase 2, Completed, Seattle Institute for Biomedical and Clinical Research; results first posted 2020-08-25

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder. Trials, record NCT01518972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01518972

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder
NCT number: NCT01518972
Status: Completed
Phases: Phase 2
Enrollment: 30 participants, actual
Lead sponsor: Seattle Institute for Biomedical and Clinical Research
Conditions: Alcohol Abuse, Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo medication
First posted: 2012-01-26
Last updated: 2020-08-25
Results first posted: 2020-08-25

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percent Drinking Days Per Week	6 weeks	Data for this measure came from the Form-42 and daily IVR (Interactive Voice Response) monitoring. The percentage of drinking days of each participant was calculated by summing the number of drinking days and comparing them with the number of total drinking days in the same week. The percentage of drinking days from each week was added and averaged to get the percentage of drinking days per week per participant. The percentage of drinking days of all participants in the Prazosin group was added and averaged to get the mean of the percentage of weekly drinking days of the Prazosin group. These steps were repeated for the Placebo group.
Primary	Percent Heavy Drinking Days Per Week	6 weeks	Data for this measure came from the Form-42 and daily IVR (Interactive Voice Response) monitoring. Heavy drinking was defined as 5 or more drinks per day for men and 4 or more drinks per day for women. The percentage of heavy drinking days of each participant was calculated by summing the number of heavy drinking days and comparing them with the total number of drinking days in the same week. The percentage of heavy drinking days from each week was added and averaged to get the percentage of heavy drinking days per week per participant. The percentage of heavy drinking days of all participants in the Prazosin group was added and averaged to get the mean of percentage of weekly heavy drinking days of the Prazosin group. These steps were repeated for the Placebo group.
Primary	Total Drinks Per Week	6 weeks	Data for this measure came from the Form-42 and daily IVR (Interactive Voice Response) monitoring. The weekly total drinks of each participant were calculated by adding the number of drinks by week. The total drinks from each week were added and averaged to get the weekly total drinks of each participant. The weekly total drinks of all participants in the Prazosin group were added and averaged to get the total drinks per week for the Prazosin group. These steps were repeated for the Placebo group.
Secondary	PTSD Symptom Assessments	6 weeks	PTSD symptoms/changes in PTSD (Post-Traumatic Stress Disorder) symptomatology was calculated using data from the IVR (interactive Voice Response) monitoring. PTSD scores were derived by computing the daily average of the item totals for overall PTSD and the symptom clusters. The rating range was 0 (not at all) to 8 (extremely). The higher the score/rating, the more severe the PTSD symptoms. The lowest and highest possible average are 0 and 8, respectively.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percent Drinking Days Per Week	6 weeks	Percent drinking days per week was examined using multilevel mixed-effects linear regression models with random slope that included treatment group, time, \& treatment group x time interaction. Time was modeled as a categorical variable.	percentage of drinking days per week	MEAN
PRIMARY	Percent Heavy Drinking Days Per Week	6 weeks	Percent heavy drinking days per week was examined using multilevel mixed-effects linear regression models with random slope that included treatment group, time, \& treatment group x time interaction. Time was modeled as a categorical variable.	Percentage of heavy drinking days/week	MEAN
PRIMARY	Total Drinks Per Week	6 weeks	The total number of drinks per week was examined using multilevel mixed-effects linear regression models with random slope that included treatment group, time, \& treatment group x time interaction. Time was modeled as a categorical variable.	drinks per week	MEAN
SECONDARY	PTSD Symptom Assessments	6 weeks	PTSD outcomes between weeks 1 and 6 were analyzed using multilevel mixed-effects linear regression models. Models were adjusted for baseline PTSD severity as measured by corresponding PSS-I scores \& sub-scores because measures comparable to the IVR PTSD measures were not available at baseline. Analyses were also adjusted for gender.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percent Drinking Days Per Week	Prazosin		18.1	95% Confidence Interval -1.1 to 37.4	percentage of drinking days per week
Percent Drinking Days Per Week	Placebo		49.3	95% Confidence Interval 31.7 to 66.9	percentage of drinking days per week
Percent Heavy Drinking Days Per Week	Prazosin		3.7	95% Confidence Interval -14.4 to 21.8	Percentage of heavy drinking days/week
Percent Heavy Drinking Days Per Week	Placebo		27.4	95% Confidence Interval 11.3 to 43.5	Percentage of heavy drinking days/week
Total Drinks Per Week	Prazosin		7.9	95% Confidence Interval -15.7 to 31.4	drinks per week
Total Drinks Per Week	Placebo		27	95% Confidence Interval 5.9 to 48.1	drinks per week
PTSD Symptom Assessments	Prazosin	Total PTSD score	3.1	95% Confidence Interval 1.9 to 4.2	units on a scale
PTSD Symptom Assessments	Placebo	Total PTSD score	2.5	95% Confidence Interval 1.4 to 3.6	units on a scale
PTSD Symptom Assessments	Prazosin	Re-experiencing	3.2	95% Confidence Interval 1.9 to 4.4	units on a scale
PTSD Symptom Assessments	Placebo	Re-experiencing	2.6	95% Confidence Interval 1.4 to 3.8	units on a scale

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Prazosin	15
Overall Study	STARTED	Placebo	15
Overall Study	COMPLETED	Prazosin	9
Overall Study	COMPLETED	Placebo	11
Overall Study	NOT COMPLETED	Prazosin	6
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Experienced 1 adverse event	General disorders	Placebo	2	14
other	Experienced 1 adverse event	General disorders	Prazosin	0	14
other	Experienced 2 adverse events	General disorders	Placebo	5	14
other	Experienced 2 adverse events	General disorders	Prazosin	1	14
other	Experienced 3 adverse events	General disorders	Placebo	7	14
other	Experienced 3 adverse events	General disorders	Prazosin	9	14

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	14
Total, all-cause mortality	Prazosin	0	14
Total, other adverse events	Placebo	14	14
Total, other adverse events	Prazosin	10	14
Total, serious adverse events	Placebo	0	14
Total, serious adverse events	Prazosin	0	14

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P20AA017839	Center for Neuroregulation in Alcohol Dependence (CeNiAD)	SAXON, ANDREW J	SEATTLE INST FOR BIOMEDICAL/CLINICAL RES	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2009 to 2010

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Prazosin vs Placebo: deaths from any cause	Trial comparisons
Prazosin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01518972

GET https://conductscience.org/api/trials/v1/NCT01518972/registered

API reference For AI assistants